Processa Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDProcessa Pharmaceuticals, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 93% provides fundamental context to the price action. Investors should exercise caution due to high volatility (173% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.29 | -5.23% | BELOW |
| 50 SMA | $2.99 | -27.32% | BELOW |
| 100 SMA | $1.75 | +24.25% | ABOVE |
| 150 SMA | $1.23 | +75.85% | ABOVE |
| 200 SMA | $0.99 | +119.39% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PCSA in an uptrend right now?
PCSA has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is PCSA overbought or oversold?
PCSA's RSI (14) is 45. The stock is in neutral territory, neither overbought nor oversold.
Is PCSA outperforming the market?
PCSA has a Relative Strength (RS) Rating of 98 out of 99. Yes, PCSA is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is PCSA in its 52-week range?
PCSA is trading at $2.17, which is 24% of its 52-week high ($8.88) and 23% above its 52-week low ($0.11).
How volatile is PCSA?
PCSA has a Beta of 0.92 and 52-week volatility of 173%. It's less volatile than the S&P 500 - generally more stable.